C4 Imaging — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

C4 Imaging is a privately held medical device company founded in 2008 (incorporated in 2010) and based in Salt Lake City, Utah. It has developed a proprietary platform of non-metallic, positive-signal MRI fiducial markers that address critical imaging artifacts, enabling more precise targeting in advanced radiation therapies like proton therapy and brachytherapy. With a commercial-stage product portfolio, the company is positioned in the growing market for image-guided radiotherapy, leveraging endorsements from leading cancer centers. Its founder, a prominent radiation oncologist from MD Anderson, provides strong clinical validation and drives its mission to improve patient outcomes through enhanced visualization.

Oncology

Technology Platform

Proprietary platform for designing and manufacturing non-metallic, multi-modality visible fiducial markers that produce a positive signal on MRI with minimal imaging artifacts and dose perturbation.

Opportunities

The global expansion of proton therapy centers and the rapid adoption of MRI-guided radiotherapy systems create a direct and growing demand for C4 Imaging's artifact-free fiducial markers.

Furthermore, the clinical push towards 'zero harm' and more precise, hypofractionated treatment regimens increases the value proposition of their technology for both academic and community cancer centers.

Risk Factors

Key risks include competition from large, entrenched medical device companies that may develop similar products, the challenge of driving market adoption and switching costs away from conventional metallic markers, and the ongoing need to secure favorable insurance reimbursement for their devices to ensure hospital affordability.

Competitive Landscape

C4 Imaging competes in the fiducial marker space against large radiotherapy device companies (e.g., Varian/Siemens Healthineers, Elekta) and specialized brachytherapy companies that offer traditional metallic markers. Its primary competitive advantage is being first-to-market with a non-metallic, MRI-positive fiducial, addressing a specific limitation in advanced imaging workflows that competitors' products exacerbate.

More companies in Diagnostics & Precision Medicine →More companies in United States →